The advantages of p-aminohippuric acid over diodrast for the measurement of the effective renal plasma flow and tubular excretory mass have been noted in a previous paper (1) . The present report describes the determination of tubular excretory capacity by p-aminohippuric acid (TmPAH) ,2 the quantitative relations between filtration rate, effective renal plasma flow, and TmPAH in 31 normal subjects, in 10 patients with essential hypertension and in 3 patients with glomerulonephritis, and presents a comparison of TmPAH with the equivalent diodrast measurement (TmD) in a number of these individuals.
The subjects were volunteers from the Third (New York University) Medical Division of Bellevue Hospital. Those considered normal were afebrile.
METHODS
The data were collected by two methods. The first, designated here as the multiple period method and identical with the method used in previous studies from this laboratory (2, 3) , consists of the determination of TmD or Tmp" by 5 or more successive urine collection periods of about 10 minutes each. The following stock solutions are used in the preparation of the infusion fluid: inulin 10 per cent, mannitol 25 per cent, diodrast 35 per cent, sodium p-aminohippurate 20 per cent. For the measurement of effective renal plasma flow and glomerular filtration rate, a priming infusion of 80 ml. of mannitol or 30 ml. of inulin and 2.3 ml. of diodrast or 4 ml. of sodium p-aminohippurate is mixed in a sterile 250 ml. flask and administered intravenously at the rate of 20 ml. per minute. This is immediately followed by a 'Aided by a grant from the Commonwealth Fund.
2A sterile solution (20 per cent) of sodium p-aminohippurate in 50 ml. ampoules and Reagent grade p-aminohippuric acid were supplied through the courtesy of the Medical-Research Division of Sharp and Dohme, Philadelphia, Pa. We are indebted to Sharp and Dohme for making available substantial quantities of these materials for clinical as well as experimental trial. sustaining infusion consisting of 80 ml. of mannitol, 70 ml. of inulin, and 10 ml. of diodrast or 20 ml. of sodium p-aminohippurate, made up to a total volume of 500 ml. with normal saline and administered intravenously at the rate of 4 ml. per minute.
For the measurement of maximal tubular excretory capacity (TmD or TmPAH), the infusion is stopped and a priming injection is made into the infusion tubing of 30 ml. of diodrast or 60 ml. of sodium p-aminohippurate, administered over a period of 10 minutes. The residual infusion is reinforced by the addition of 0.18 ml. of diodrast or 0.43 ml. of sodium p-aminohippurate per ml. of infusion remaining in the flask, after which the infusion rate is restored to 4 ml. per minute. infusion tubing, with the infusion stopped, the injection requiring about 10 minutes, and then 0.43 ml. of sodium p-aminohippurate are added to each ml. of the residual infusion, after which the rate of infusion is restored to 4 ml. per minute. Twenty minutes from the end of the priming injection, the bladder is emptied and rinsed and a blood sample (B3) is taken. Twenty minutes later, another blood sample (B,) is taken and the second urine specimen (U2) collected by rinsing. The concentrations of the essential substrates as determined in the separated plasma from the 4 blood samples are plotted on semilogarithmic paper against time and the mean plasma concentrations determined by interpolation to the middle of the 2 urine collection periods. These values, with the analytical data derived from the 2 urine samples, are used to calculate the effective renal plasma flow, filtration rate, and TmPAH.
(TmD measurements were not made by the single period method in this paper, but this procedure will fit into the single period method, the doses required being the same as those described above for the multiple period method. ) The above quantities of diodrast and sodium p-aminohippurate in the sustaining infusion are recommended for patients with normal or moderately depressed renal function, and must be proportionately reduced in patients with marked functional impairment. This is essential in the (6) and mannitol by the method of Smith, Finkelstein, and Smith (7) . The p-aminohippuric acid plasma blank is determined additively, i.e., by the addition of a known amount of substrate to the Bo filtrate (1) . Inulin and mannitol plasma blanks are determined by adding known quantities of substrate to a sample of Bo plasma, prior to treatment with yeast and precipitation.4 Equivalent aqueous dilu- 4 Re-examination of the inulin method, now in process, reveals that apparently fructose-free inulin (repeatedly recrystallized) is taken up to an appreciable extent by yeast and recoveries are therefore less than 100 per cent. This deficient recovery tends to be compensated by an inulinoid blank derived from the yeast itself.
Loss of inulin onto yeast is not a significant source of error if plasmas and urines are yeasted and precipitated in an identical manner. The appropriate blank to be deducted from the plasma may be determined additively in the Bo filtrate, i.e., by diluting a small quantity of stand- (1) .
During the administration of the priming dose of sodium p-aminohippurate, nearly all patients complained of a sensation of warmth which began in the lumbar region, the epigastrium, or the perineum and, at times, was felt over the entire body. The sensation persisted until 3 to 5 minutes after the injection had been completed. Despite ard inulin solution with the Bo filtrate prepared without the addition of inulin. The same procedure is applicable to mannitol. subjects using the single (Table I) and an intense subjective sensation of warmth, the rectal temperature remained normal and rio change in skin color was visible, although in some individuals perspiration was noted. The pulse rate and blood pressure remained unchanged. The only other reactions were occasional headache or nausea which disappeared after cessation of the priming dose. Three out of 43 patients vomited and 2 had a formed bowel movement about 5 minutes after the end of the injection. In most instances, symptoms could be controlled or prevented by slowing the rate of injection and in no case was it necessary to discontinue administration of the drug.
RESULTS
Four sets of data are presented in the tables: a comparison of TmD and TmpAr in 10 normal subjects (i.e., convalescent patients who were free of immediate evidences or history of renal disease), these values being determined on separate occasions and each datum representing the mean of 5 or more successive urine collection periods (Table I) TmpAH in 10 subjects with essential hypertension (Table III) ; and a similar comparison in 3 subjects with glomerulonephritis (Table IV) . The data obtained by the multiple (Table I ) and single period (Table II) TmPAH. This value, as cited in Table II, is 77.5 + 12.9. Since the total number of subjects is too small to permit subdivision by sexes, the establishment of a mean value for each sex must await the collection of more data.
The ratio TmPAH/TmD, when calculated on a molar basis, averages (2.33 -+-0.32), a figure considerably higher than in the dog, in which species it has a value of approximately 1.0 (1). This species difference has no explanation at the present time. In the limited number of patients stud- ied here, this ratio remains unchanged in the presence of essential hypertension and glomerulonephritis, indicating that in these subjects the loss of capacity on the part of the renal tubules to excrete diodrast is accompanied by a parallel loss of capacity to excrete p-aminohippuric acid. Whether or not this relationship will hold at all stages and in all forms of renal disease remains to be determined.
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SUMMARY
Procedures are presented for the determination of the effective renal plasma flow (CPAH) and the maximal rate of tubular excretion (TmPAH) of p-aminohippuric acid.
The sion. In 1 patient with acute and 2 with chronic diffuse glomerulonephritis, the ratio appears to be similar.
The intravenous administration of relatively large doses of sterile solutions of sodium p-aminohippurate causes no disturbing symptoms if the rate of injection is approximately 6 ml. of a 20 per cent solution per minute.
